The development of immunotherapeutic strategies for the treatment of leukemia and other cancers has long been of interest. Natural killer (NK) cells represent one component of the innate immune system and have the ability to both lyse target cells and produce immunoregulatory cytokines. Thus, these large granular lymphocytes have been the subject of intense investigation for their antitumor effects. Human NK cells comprise approximately 10-15% of all peripheral blood lymphocytes and are defined by the presence of the CD56 cell surface antigen and the lack of CD3. 1 Two subsets of NK cells can be distinguished based on their cell surface density of CD56. The majority (ෂ90%) of human NK cells are CD56 dim and express high levels of Fc RIII (CD16), which mediates antibody-dependent cellular cytotoxicity, while a minority (ෂ10%) of NK cells are CD56 bright CD16 dim/neg . 2 NK cells have the unique ability to lyse tumor target cells without prior sensitization, in contrast to T lymphocytes, which depend on activation and presentation of specific antigens associated with HLA molecules to elicit a cytotoxic effect. Because of this fact, there has been a great deal of interest in understanding the mechanisms whereby NK cells mediate their cytotolytic effects. It is now clear that NK receptors (NKRs) for MHC class I molecules are critical for the recognition of normal vs transformed and/or foreign cells. In the setting of therapy for acute myeloid leukemia (AML) and other hematologic malignancies, there is now good evidence to suggest that mismatch of donor NKRs and recipient class I molecules in haplotypemismatched BMT may have a beneficial effect when that mismatch is in the donor vs leukemia direction. 3 Thus, immunotherapeutic strategies targeting NK cells have the potential to be beneficial for the treatment of leukemia.
It has been known for decades that NK cells develop within the bone marrow (BM) microenvironment and numerous studies have definitively identified the cytokine interleukin (IL)-15 as the critical factor necessary for the development of human and murine NK cells. 4 8 Clinical trials have demonstrated that treatment of leukemia patients with low-dose IL-2 can safely drive NK cell development and expansion. 9 However, administration of additional NK differentiation factors such as flt3 ligand or ckit ligand in combination with IL-2 has the potential to enhance NK cell differentiation and expansion in the setting of malignancy.
Two distinct populations of human NK cells can be identified in the peripheral blood of all healthy donors based upon cell surface density of CD56. 10 In addition to their cytotoxic effects, NK cells also constitutively express receptors for monocyte-derived cytokines (monokines) and produce immunoregulatory cytokines such as IFN-␥, in response to monokine stimulation. NK cellderived IFN-␥ plays a critical role in the immune response to infection and possibly in NK cell tumor immunosurveillance. We have recently reported that CD56 bright NK cells have the capacity to produce abundant cytokines, including IFN-␥, following monokine stimulation compared to the CD56 dim NK subset, which produces very low levels of cytokines. 12 Collectively, the data support a model whereby CD56 bright and CD56 dim NK cells represent functionally distinct subsets of human NK cells, although very little is known about the developmental relationship between these subsets. Therefore, knowledge of the distinct functional attributes of human NK cell subsets and the factors involved in their differentiation and expansion may enable us to design strategies that preferentially activate that subset with the greatest therapeutic potential for a particular cancer.
The mechanisms whereby an NK cell recognizes a target cell with subsequent activation or inhibition of killing are complex and are just now being elucidated. 13 NKRs recognizing self-MHC class I molecules have been identified in both mouse and man and appear to be critical for the inhibition of NK cell lysis of normal 'self' cells. NKRs exist in both activating and inhibitory forms. Inhibitory NKRs are specific for classical (eg HLA-A, B or C) or nonclassical (eg HLA-E or G) class I while activating NKRs also recognize 'class I-like' molecules. Ordinarily, when an NK cell encounters a normal host cell, class I molecules expressed on the surface of that 'self' cell are engaged by the NK cell's inhibitory receptors and a strong inhibitory signal is transduced via an immunoreceptor tyrosine-based inhibitor motif in the cytoplasmic domain of the NKR. This signal acts to prevent NK cell activation and consequent cytolysis. However, when an NK cell's inhibitory receptors fail to recognize self class I, such as on a foreign or transformed cell, the inhibitory signal is absent and NK cell activation can proceed. In contrast, when activating NKRs are engaged by their ligands, NK cell cytolytic and cytokine-producing programs are activated to allow attack of target cells. These receptors do this via an association with membraneanchored, activation-inducing adapters such as DAP12 or DAP10 that activate immunoreceptor tyrosine-based activation motif or PI3-kinase pathways respectively. 13 Activation of NK cytotoxicity is likely mediated by a balance of inhibitor and activating NKR signals as well as various other adhesion and/or costimulatory molecules. Three major superfamilies of NKRs have been described in humans: the killer cell Ig-like superfamily, which primarily recognize HLA A, B and C; the C-type lectin superfamily, which includes CD94 and NKG2 receptors recognizing nonclassical HLA-E molecules; and a recently described class of natural cytotoxicity receptors with unknown ligands.
14 Regulation of NK cell cytotoxicity by NKRs is relevant in the setting of haplotype-mismatched bone marrow transplantation (BMT), where the possibility exists that inhibitory NKRs on donor-derived NK cells will fail to recognize recipient leukemic blasts and exert a graft-versus-host effect or vice versa. Elegant work in support of this theory comes from a retrospective analysis by the Velardi laboratory at the University of Perugia. 3 In this study, the investigators examined the role of inhibitory NKRs in mediating a donor NK vs leukemia effect. Donor-recipient pairs where at least one of the haploidentical donor's inhibitory receptors would fail to recognize a class I ligand on the patient's leukemic blasts had a higher rate of engraftment and lower incidence of leukemic relapse, compared to those without the potential for alloreactive NK cells. This NK vs leukemia effect was borne out in laboratory analyses showing that donor NK clones were able to lyse patient leukemic blasts. There was no graft-versus-host disease observed in these patients, suggesting NK cells may, in the setting of allogeneic transplantation, mediate a selective NK vs leukemia reaction. 3 In addition to inhibitory receptors, NK cell activating receptors are thought to play a major role in target cell recognition. One nonclassical activating NKR is the homodimeric C-type lectin receptor, NKG2D, whose ligands are not MHC class I molecules but MHC 'class I-like'. In humans, these ligands include MICA and MICB and the RAE-1-like molecules (also known as UL-16 binding proteins, ULBPs). 13 These ligands are Leukemia absent or expressed at low density in normal tissues, but are up-regulated in response to stress, infection, and malignant transformation. 15 While MICA/B were originally thought to be restricted to epithelial cells, they have recently been identified on multiple types of tumor cell lines including leukemia, and lymphoma lines that were specifically lysed by NK cell clones expressing NKG2D. 16 Thus, therapeutic strategies aimed at up-regulation of activating ligands and/or NKG2D could further potentiate the antileukemic effects of NK cells.
In summary, advances in our understanding of basic human NK cell biology, including NK cell differentiation and the mechanisms of NK cell target recognition have led to the initial design of rational therapeutic strategies for the treatment of leukemia. Further investigation of the biology of these potent immune effectors will likely result in additional novel immune-based strategies for the treatment of cancer.
